secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVELATION BIOSCIENCES, INC. (REVB)
CIK:        0001810560
Form:       8-K
Filed at:   2025-12-03T23:59:59+00:00
Accession:  0001193125-25-306915
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 3.03, 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Revelation Biosciences reports positive Phase 1b Gemini results; plans Phase 2/3 AKI study in 2026
--------------------------------------------------------------------------------

- Phase 1b CKD study completed with positive results; Gemini rebalances inflammation at cellular level.
- CEO expects FDA meeting later in 2025 to discuss clinical/regulatory pathways for acute kidney injury.
- Company plans to start Phase 2/3 AKI study in 2026, building manufacturing and CRO infrastructure.
- Stockholders approved share issuance related to warrants; warrant expiration fixed to Dec 3, 2030.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810560/000119312525306915/0001193125-25-306915-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810560/000119312525306915/revb-20251203.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-306915

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer